Drug safety assurance through clinical genotyping: Near-term considerations for a system-wide implementation of personalized medicine

Personalized Medicine

Volumn 5, Issue 4, 2008, Pages 387-397

  Kane, Michael D ^a,b   Springer, John A ^a   Sprague, Jon E ^c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

Clinical genotyping; Data management; Electronic health record; Personalized medicine; Pharmacogenetics; SNP

Indexed keywords

AMINOPHYLLINE; AMIODARONE; ATORVASTATIN; BETAXOLOL; CAFFEINE; CARBAMAZEPINE; CARVEDILOL; CLARITHROMYCIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DILTIAZEM; DNA; FLUOXETINE; FLUTAMIDE; GLIMEPIRIDE; LOSARTAN; PROPRANOLOL; WARFARIN;

ACCESS TO INFORMATION; ALLELE; AREA UNDER THE CURVE; ARTICLE; DNA DETERMINATION; DNA SCREENING; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; ELECTRONIC MEDICAL RECORD; GENETIC LINKAGE; GENETIC RISK; GENOMICS; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; INFORMATION SYSTEM; MEDICAL RESEARCH; PATIENT CARE; PHARMACOGENETICS; PHARMACOGENOMICS; POINT OF CARE TESTING; POLITICAL SYSTEM; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 50549104859     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.4.387     Document Type: Article

References (12)

1. Vizirianakis IS: Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin. Pharmacokinet. 46, 807-824 (2007).
2. Swen JJ, Huizinga TW, Gelderblom H et al.: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4(8), E209 (2007).
3. Gurwitz D, Lunshof JE, Dedoussis G et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 5, 221-225 (2005).
4. Meur Y, Djebli N, Szelag J et al.: CYP3A5*3 influences sirolius oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60 (2006).
5. Vizirianakis IS: Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? Pharmacogenomics 6, 701-711 (2005).
6. Thornton M, Gladwin A, Payne R et al.: Automation and validation of DNA- banking systems. Drug Discov. Today 10, 1369-1375 (2005).
7. Gregg AR, Simpson JL: Genetic screening for cystic fibrosis. Obstet. Gynecol. Clin. North Am. 29(2), 329-340 (2002).
8. Payne K: Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Pharmacogenomics 9, 1-4 (2008).
9. Shabo Shvo A: How can the emerging patient-centric health records lower costs in pharmacogenomics? Pharmacogenomics 8, 507-511 (2007).
10. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo) 125(4), 803-808 (1999).
11. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14(12), 813-822 (2004).
12. Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299(3), 825-831 (2001).